



Press Release

for  
**immediate**  
release

## Teva Signs New \$3.0 Billion Syndicated Revolving Credit Facility

- New Facility to Replace Existing \$2.5 Billion Facility -
- Secures Teva's Liquidity through Revolving Credit Lines -

**Jerusalem, Israel, December 18, 2012** – Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it has entered into a new five-year, \$3.0 billion unsecured revolving credit facility, which replaces its existing \$2.5 billion credit facility.

“By signing this new revolving credit facility, with its increased size and extended term, we took another step on our recently announced new strategy and secured ample liquidity to support Teva's future growth,” stated Eyal Desheh, Executive Vice President and Chief Financial Officer of Teva. “We were very pleased to see the significant oversubscription, demonstrating the strong desire from our relationship banks, as well as from additional new banks, to commit to this new facility.”

Citi and HSBC Bank plc are Coordinating Bookrunners and Mandated Lead Arrangers for the facility. The syndicate also includes Barclays Bank PLC, BNP Paribas, Credit Suisse Securities (USA) LLC, Goldman Sachs Bank USA, J.P. Morgan Limited and Morgan Stanley Senior Funding, Inc. as Bookrunners and Mandated Lead Arrangers, and Bank Leumi le-Israel B.M, DNB Bank ASA, PNC Bank and RBC Capital Markets as Lead Arrangers.

### About Teva

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 850 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached \$18.3 billion in net revenues in 2011.

---

|              |                                 |               |                  |
|--------------|---------------------------------|---------------|------------------|
| IR Contacts: | <b>Kevin C. Mannix</b>          | United States | (215) 591-8912   |
|              | <b>Joseph Marczely</b>          | United States | (267) 468-4281   |
|              | <b>Tomer Amitai</b>             | Israel        | 972 (3) 926-7656 |
| PR Contacts  | <b>Hadar Vismunski-Weinberg</b> | Israel        | 972 (3) 926-7687 |
|              | <b>Denise Bradley</b>           | United States | (215) 591-8974   |



# Press Release

for  
**immediate**  
release

## **Teva's Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995:**

This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialize additional pharmaceutical products, competition from the introduction of competing generic equivalents and the impact of increased governmental pricing pressures, the effects of competition on revenues of our innovative products, especially Copaxone® (including competition from innovative orally-administered alternatives, as well as from potential generic equivalents), potential liability for revenues of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic version of Protonix®, the extent to which we may obtain U.S. market exclusivity for certain of our new generic products, the extent to which any manufacturing or quality control problems damage our reputation for high quality production and require costly remediation, our ability to identify, consummate and successfully integrate acquisitions (including the acquisition of Cephalon), our ability to achieve expected results through our innovative R&D efforts, dependence on the effectiveness of our patents and other protections for innovative products, intense competition in our specialty pharmaceutical businesses, uncertainties surrounding the legislative and regulatory pathway for the registration and approval of biotechnology-based products, our potential exposure to product liability claims to the extent not covered by insurance, any failures to comply with the complex Medicare and Medicaid reporting and payment obligations, our exposure to currency fluctuations and restrictions as well as credit risks, the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement, adverse effects of political or economical instability, major hostilities or acts of terrorism on our significant worldwide operations, increased government scrutiny in both the U.S. and Europe of our agreements with brand companies, interruptions in our supply chain or problems with our information technology systems that adversely affect our complex manufacturing processes, the impact of continuing consolidation of our distributors and customers, the difficulty of complying with U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority requirements, potentially significant impairments of intangible assets and goodwill, potential increases in tax liabilities resulting from challenges to our intercompany arrangements, the termination or expiration of governmental programs or tax benefits, any failure to retain key personnel or to attract additional executive and managerial talent, environmental risks and other factors that are discussed in our Annual Report on Form 20F for the year ended December 31, 2011 and in our other filings with the U.S. Securities and Exchange Commission.

###

---

|              |                                 |               |                  |
|--------------|---------------------------------|---------------|------------------|
| IR Contacts: | <b>Kevin C. Mannix</b>          | United States | (215) 591-8912   |
|              | <b>Joseph Marczely</b>          | United States | (267) 468-4281   |
|              | <b>Tomer Amitai</b>             | Israel        | 972 (3) 926-7656 |
| PR Contacts  | <b>Hadar Vismunski-Weinberg</b> | Israel        | 972 (3) 926-7687 |
|              | <b>Denise Bradley</b>           | United States | (215) 591-8974   |

## טבע חותמת על קו אשראי חדש בסינדיקט בסכום של 3 מיליארד דולר

- קו האשראי החדש יחליף קו אשראי קיים בסכום של 2.5 מיליארד דולר -
- יבטיח את נזילות טבע באמצעות קווי אשראי מתחדשים -

ירושלים, ישראל, 18 בדצמבר 2012 - טבע תעשיות פרמצבטיות בע"מ (סימול: TEVA) הודיעה היום כי חתמה על קו אשראי חדש בסינדיקט, ללא בטחונות, בסכום של 3 מיליארד דולר ולתקופה של חמש שנים. קו אשראי זה מחליף קו אשראי קיים בסכום של 2.5 מיליארד דולר.

"באמצעות החתימה על קו אשראי חדש זה, הגדול מקודמו בסכום ובתקופה, התקדמנו צעד נוסף באסטרטגיה החדשה של טבע שהוכרזה לאחרונה והבטחנו נזילות מספקת לתמיכה בצמיחה העתידית של החברה," אמר איל דשא, סמנכ"ל בכיר ומנהל הכספים הראשי של טבע. "אנו מרוצים מאד מחיתום-היתר של קו זה, המעיד על נכונותם החזקה של הבנקים איתם אנחנו עובדים, כמו גם בנקים חדשים נוספים, לקחת בו חלק."

הבנקים Citi ו-HSBC Bank plc הם החתמים המובילים והמארגנים של קו אשראי זה. הסינדיקט כולל גם את Goldman Sachs Bank, Credit Suisse Securities (USA) LLC, BNP Paribas, Barclays Bank PLC, J.P. Morgan Limited, USA, Morgan Stanley Senior Funding, Inc. ו-Bank Leumi, ו-RBC Capital Markets, PNC Bank, DNB Bank ASA, le-Israel B.M. כמארגנים.

### אודות טבע

טבע תעשיות פרמצבטיות בע"מ (NYSE: TEVA) היא חברת תרופות גלובלית המחויבת לפיתוח ולשיווק תרופות באיכות גבוהה בהישג יד בכל מקום בעולם. החברה, שבסיסה בישראל, עוסקת ביצור תרופות גנריות, תרופות ייחודיות וממותגות וביצור חומרי גלם פעילים לתעשייה הפרמצבטית. טבע מובילה את שוק התרופות הגנריות העולמי, עם נוכחות ביותר מ-60 מדינות ועם סל תרופות של יותר מ-850 מולקולות הנמכר ביותר מ-120 שווקים. התרופות הייחודיות והממותגות של החברה מתמקדות בתחומי מערכת העצבים המרכזית, האונקולוגיה, הכאב, הנשימה ובריאות האישה, כמו גם בתחום התרופות הביולוגיות. טבע מעסיקה כיום כ-46,000 איש. מכירות החברה הסתכמו בשנת 2011 ב-18.3 מיליארד דולר.

**Teva's Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995:**

This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialize additional pharmaceutical products, competition from the introduction of competing generic equivalents and the impact of increased governmental pricing pressures, the effects of competition on revenues of our innovative products, especially Copaxone® (including competition from innovative orally-administered alternatives, as well as from potential generic equivalents), potential liability for revenues of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic version of Protonix®, the extent to which we may obtain U.S. market exclusivity for certain of our new generic products, the extent to which any manufacturing or quality control problems damage our reputation for high quality production and require costly remediation, our ability to identify, consummate and successfully integrate acquisitions (including the acquisition of Cephalon), our ability to achieve expected results through our innovative R&D efforts, dependence on the effectiveness of our patents and other protections for innovative products, intense competition in our specialty pharmaceutical businesses, uncertainties surrounding the legislative and regulatory pathway for the registration and approval of biotechnology-based products, our potential exposure to product liability claims to the extent not covered by insurance, any failures to comply with the complex Medicare and Medicaid reporting and payment obligations, our exposure to currency fluctuations and restrictions as well as credit risks, the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement, adverse effects of political or economical instability, major hostilities or acts of terrorism on our significant worldwide operations, increased government scrutiny in both the U.S. and Europe of our agreements with brand companies, interruptions in our supply chain or problems with our information technology systems that adversely affect our complex manufacturing processes, the impact of continuing consolidation of our distributors and customers, the difficulty of complying with U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority requirements, potentially significant impairments of intangible assets and goodwill, potential increases in tax liabilities resulting from challenges to our intercompany arrangements, the termination or expiration of governmental programs or tax benefits, any failure to retain key personnel or to attract additional executive and managerial talent, environmental risks and other factors that are discussed in our Annual Report on Form 20F for the year ended December 31, 2011 and in our other filings with the U.S. Securities and Exchange Commission.

###